Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helge Taubert

Showing results (161-170 of 168) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 168 results.
The Journal of Pathology. Clinical Research|March 20, 2024
A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testingMiriam Angeloni, Thomas van Doeveren, Sebastian Lindner, et al.
Journal for Immunotherapy of Cancer|May 26, 2020
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapyMarkus Eckstein, Pamela Strissel, Reiner Strick, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumabMarkus Eckstein, Philipp Erben, Maximilian C Kriegmair, et al.
European Urology|November 13, 2022
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint InhibitionFranziska Erlmeier, Niklas Klümper, Laura Landgraf, et al.
Cancer Immunology Research|April 17, 2019
The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer SubtypesCarolin Pfannstiel, Pamela L Strissel, Katherine B Chiappinelli, et al.
European Urology Oncology|August 10, 2023
Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient OutcomesMarkus Eckstein, Christian Matek, Paul Wagner, et al.
European Urology Oncology|October 9, 2023
Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)]Markus Eckstein, Christian Matek, Paul Wagner, et al.
Journal of Clinical Pathology|September 29, 2021
Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohortFriederike Kullmann, Pamela L Strissel, Reiner Strick, et al.
Pageof 17

Showing results (161-170 of 168) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 168 results.
The Journal of Pathology. Clinical Research|March 20, 2024
A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testingMiriam Angeloni, Thomas van Doeveren, Sebastian Lindner, et al.
Journal for Immunotherapy of Cancer|May 26, 2020
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapyMarkus Eckstein, Pamela Strissel, Reiner Strick, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumabMarkus Eckstein, Philipp Erben, Maximilian C Kriegmair, et al.
European Urology|November 13, 2022
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint InhibitionFranziska Erlmeier, Niklas Klümper, Laura Landgraf, et al.
Cancer Immunology Research|April 17, 2019
The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer SubtypesCarolin Pfannstiel, Pamela L Strissel, Katherine B Chiappinelli, et al.
European Urology Oncology|August 10, 2023
Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient OutcomesMarkus Eckstein, Christian Matek, Paul Wagner, et al.
European Urology Oncology|October 9, 2023
Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)]Markus Eckstein, Christian Matek, Paul Wagner, et al.
Journal of Clinical Pathology|September 29, 2021
Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohortFriederike Kullmann, Pamela L Strissel, Reiner Strick, et al.
Pageof 17